Our Scientific Advisory Board

Our 20-strong team boasts deep experience in RNA biology, bioinformatics analytics, neuro-translation and development.

Prof. Roger Barker

University of Cambridge

  • Neurologist-scientist specialising in PD and HD
  • Key role in clinical trials in PD and HD
  • Biomarkers to assess disease onset and progression
  • Exploring therapeutic options including genetic therapies and cell transplantation

Dr Tom Massey

University of Cardiff

  • Neurologist specialising in HD & repeat expansion disorders
  • Clinical trials in HD
  • Active laboratory researching DDR in HD using iPSC, CRISPR and biochemistry to link clinical phenotype to mechanism
  • Exploring therapeutic options including genetic therapies

Dr Irina Antonijevic

Independent Consultant

  • CMO EveryONE Medicines
  • CMO Triplet Therapeutics
  • VP Translation Wave Life Sciences
  • Head Early Development Sanofi-Genzyme Medical Director, CHDI
  • Resident Physician Psychiatry, Max Plank Institute

Dr Eric Marcusson

Independent Consultant

  • Providence Therapeutics: Cofounder, CSO
  • Deep Genomics: SAB
  • Regulus: Snr Director
  • Isis Pharma: Director
  • Post-doctoral studies in oligonucleotide trafficking

Prof. Jim Gusella

MGH, Harvard

  • Human geneticist
  • Identification of susceptibility and modifier genes
  • Characterisation of these genes
  • Led GeM-HD consortium that ID’d DDR genes through large GWAS studies
  • Exploring therapeutic options including genetic therapies

Prof. Jeff Long

University of Iowa

  • Professor of Biostatistics & Psychiatry and HD expert
  • Development of statistical models for progression in neurodegenerative diseases focusing on longitudinal and time-to-event models (e.g. PIN-HD)
  • CHDI-funded biostatistical analysis of HD natural history studies, Head Biostatistician for PREDICT-HD

Dr Ralf Reilmann

George Huntington Institute

  • Neurologist-scientist specialising in HD
  • Founder & CEO of the George-Huntington-Institute (Muenster, Germany)
  • Established a cohort of >1100 PwHD
  • PI on 15 HD clinical trials
  • Development / standardisation of functional endpoints in HD

Dr Jennifer Sims

Independent consultant

  • More than 30 years non-clinical biologic drug development experience
  • Expert preclinical Assessor, MHRA
  • Head of BioPharma Safety Assessment Group, MedImmune
  • Head of Translational Science & Safety, Novartis Biologics

Our vision

Building the leading platform for physiological upregulation of neurodegenerative disease targets to enable truly disease-modifying therapies.

Our approach

Deep expertise & unique capabilities in RNA biology & neurodegeneration

High value targets

Ready to scale

Learn more

Our programmes

Preventing the progression of Huntington’s Disease

Discover more

Our news

View all